The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience.

Q2 Medicine Infezioni in Medicina Pub Date : 2023-01-01 DOI:10.53854/liim-3103-5
Giulio Rizzetto, Daisy Gambini, Andrea Maurizi, Elisa Molinelli, Edoardo De Simoni, Francesco Pallotta, Lucia Brescini, Oscar Cirioni, Annamaria Offidani, Oriana Simonetti, Andrea Giacometti
{"title":"The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience.","authors":"Giulio Rizzetto,&nbsp;Daisy Gambini,&nbsp;Andrea Maurizi,&nbsp;Elisa Molinelli,&nbsp;Edoardo De Simoni,&nbsp;Francesco Pallotta,&nbsp;Lucia Brescini,&nbsp;Oscar Cirioni,&nbsp;Annamaria Offidani,&nbsp;Oriana Simonetti,&nbsp;Andrea Giacometti","doi":"10.53854/liim-3103-5","DOIUrl":null,"url":null,"abstract":"<p><p>Antibiotic resistance of Gram-positive and Gramnegative bacteria is becoming increasingly prevalent. For this reason, the search for new molecules that can overcome current resistance and also recover antibiotics that are no longer effective is becoming increasingly urgent. Our research group at the 'Polytechnic University of Marche' managed to study the effectiveness of certain antimicrobial peptides (AMPs). We decided to review our experience with AMPs by classifying them according to their origin and evaluating their effect on Gram-negative and Gram-positive bacteria. AMPs can derive from mammals, amphibians, microorganisms, and insects. In conclusion, our research experience shows that the richest source of AMPs are amphibians. However, the studies done are mainly in vitro or in animal models, requiring further human studies to assess the efficacy and safety of these molecules. AMPs may be a new therapeutic option for infections sustained by multi-resistant micro-organisms and for overcoming the mechanisms of resistance to antibiotics currently used. In particular, combining AMPs with antibiotics, including those with limited antimicrobial activity due to antimicrobial resistance, has often shown a synergistic effect, increasing or restoring their efficacy. The possibility of using manageable and relatively safe antibiotics again is crucial, considering the widespread increase in bacterial resistance in hospitals and the community. Despite a plethora of research on AMPs and their application as potential treatment on infectious diseases, this area needs further exploration. There is evidence that the characteristics of AMPs can seriously improve through structural chemical modifications and different delivery systems to become alternatives drugs to conventional antibiotics. The aim is to provide an overview of the possible sources from which AMPs are extracted, evaluating their action exclusively on Gram-positive and negative bacteria. This is to determine, based on our experience, which might be the most promising sources of AMPs for future research as well.</p>","PeriodicalId":52423,"journal":{"name":"Infezioni in Medicina","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495054/pdf/1124-9390_31_3_2023_306-322.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infezioni in Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3103-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Antibiotic resistance of Gram-positive and Gramnegative bacteria is becoming increasingly prevalent. For this reason, the search for new molecules that can overcome current resistance and also recover antibiotics that are no longer effective is becoming increasingly urgent. Our research group at the 'Polytechnic University of Marche' managed to study the effectiveness of certain antimicrobial peptides (AMPs). We decided to review our experience with AMPs by classifying them according to their origin and evaluating their effect on Gram-negative and Gram-positive bacteria. AMPs can derive from mammals, amphibians, microorganisms, and insects. In conclusion, our research experience shows that the richest source of AMPs are amphibians. However, the studies done are mainly in vitro or in animal models, requiring further human studies to assess the efficacy and safety of these molecules. AMPs may be a new therapeutic option for infections sustained by multi-resistant micro-organisms and for overcoming the mechanisms of resistance to antibiotics currently used. In particular, combining AMPs with antibiotics, including those with limited antimicrobial activity due to antimicrobial resistance, has often shown a synergistic effect, increasing or restoring their efficacy. The possibility of using manageable and relatively safe antibiotics again is crucial, considering the widespread increase in bacterial resistance in hospitals and the community. Despite a plethora of research on AMPs and their application as potential treatment on infectious diseases, this area needs further exploration. There is evidence that the characteristics of AMPs can seriously improve through structural chemical modifications and different delivery systems to become alternatives drugs to conventional antibiotics. The aim is to provide an overview of the possible sources from which AMPs are extracted, evaluating their action exclusively on Gram-positive and negative bacteria. This is to determine, based on our experience, which might be the most promising sources of AMPs for future research as well.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗革兰氏阳性和革兰氏阴性抗菌肽的来源:我们的研究经验。
革兰氏阳性和革兰氏阴性细菌的抗生素耐药性日益普遍。出于这个原因,寻找能够克服当前耐药性并恢复不再有效的抗生素的新分子变得越来越紧迫。我们在马尔凯理工大学的研究小组成功地研究了某些抗菌肽(amp)的有效性。我们决定回顾我们在抗菌肽方面的经验,根据它们的来源对它们进行分类,并评估它们对革兰氏阴性菌和革兰氏阳性菌的影响。amp可以来自哺乳动物、两栖动物、微生物和昆虫。总之,我们的研究经验表明,AMPs最丰富的来源是两栖动物。然而,这些研究主要是在体外或动物模型中进行的,需要进一步的人体研究来评估这些分子的有效性和安全性。抗菌肽可能是治疗多重耐药微生物感染和克服目前使用的抗生素耐药机制的一种新的治疗选择。特别是,抗菌肽与抗生素联合使用,包括那些由于抗菌素耐药性而抗菌活性有限的抗生素,往往显示出协同效应,增加或恢复其功效。考虑到医院和社区细菌耐药性的普遍增加,再次使用可管理和相对安全的抗生素的可能性至关重要。尽管对抗菌肽及其在感染性疾病治疗方面的潜在应用进行了大量研究,但这一领域仍需进一步探索。有证据表明,通过结构化学修饰和不同的给药系统,抗菌肽的特性可以得到显著改善,成为传统抗生素的替代药物。目的是概述从何处提取抗菌肽的可能来源,评估其仅对革兰氏阳性和阴性细菌的作用。根据我们的经验,这是为了确定哪些可能是未来研究中最有希望的amp来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Infezioni in Medicina
Infezioni in Medicina Medicine-Infectious Diseases
CiteScore
8.40
自引率
0.00%
发文量
62
期刊介绍: The Journal publishes original papers, in Italian or in English, on topics concerning aetiopathogenesis, prevention, epidemiology, diagnosis, clinical features and therapy of infections, whose acceptance is subject to the referee’s assessment. The Journal is of interest not only to infectious disease specialists, microbiologists and pharmacologists, but also to internal medicine specialists, paediatricians, pneumologists, and to surgeons as well. The Editorial Board includes experts in each of the above mentioned fields.
期刊最新文献
The current state of knowledge on dracunculiasis: a narrative review of a rare neglected disease Historical account of clinical observations on leprosy and related manifestations in the Comacchio area, Italy, in the XIX century Clinical utility of intrabronchial antifungal instillation in a complicated case of chronic pulmonary aspergillosis: case report and systematic review of literature Did the updated Duke criteria missed Erysipelothrix rhusiopathiae from the list of typical microorganisms causing infective endocarditis? The role of long-acting antibiotics in the clinical practice: a narrative review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1